Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

March’s top stories: GSK’s preterm labour trial, Amgen and Onyx’s Kyprolis drug

GSK started its Phase III programme to evaluate retosiban for spontaneous preterm labour, Amgen and Onyx's multiple myeloma drug Kyprolis meets primary endpoint in Phase III trial, and Celgene reported positive results from Phase III LIBERATE trial of plaque psoriasis drug, Otezla. Drugdevelopment-technology.com wraps-up key headlines from March.

Go Top